Growth Factors in Thoracic Cancers
A special issue of Biomolecules (ISSN 2218-273X). This special issue belongs to the section "Cellular Biochemistry".
Deadline for manuscript submissions: closed (31 August 2022) | Viewed by 3227
Special Issue Editors
Interests: growth factors in cancer; malignant pleural mesothelioma; fibroblast growth factor; activin; optogenetics in cancer research
Interests: surgical oncology; multimodality treatment approaches; minimal invasive surgery; interventional bronchoscopy; experimental targeted therapy in mesothelioma and lung cancer; genomic profiling of mesothelioma and lung cancer; biomarkers
2. Center for Cancer Research, Medical University of Vienna, Borschkegasse 8a, 1090 Vienna, Austria
Interests: malignant pleural mesothelioma; small cell lung cancer; fibroblast growth factors in cancer; EMT and cell migration; YB-1; microRNAs in cancer
Special Issue Information
Dear Colleagues,
Growth factors are indispensable signaling molecules for cell communication. They control not only cell growth but numerous additional cell behaviors including differentiation, survival, and migration. Deregulated expression of growth factors is found in many types of cancers and contributes to tumor growth, neoangiogenesis, immune evasion, and metastasis. On the one hand, specific growth factors have become important therapeutic targets and relevant biomarkers in clinical applications. On the other hand, new roles of already well-known growth factors or of hitherto less explored growth factors are constantly being discovered. This Special Issue welcomes work on all aspects of growth factors in thoracic cancers including lung cancer, esophageal cancer, malignant pleural mesothelioma, and thymic malignancies. In all of these cancers, growth factors fundamentally contribute to tumorigenesis not only via cell-autonomous functions but also via the tumor microenvironment. Nevertheless, many aspects of growth factor biology in these cancers and of their application for the benefit of patients still remain to be elucidated. We invite original research papers in the thoracic cancer field addressing growth factor functions, regulation of their expression and secretion, advances in analysis methods, and novel uses as biomarkers and/or therapy targets. Expert reviews discussing any of the above topics are also highly welcome.
Prof. Dr. Michael Grusch
Prof. Dr. Mir Alireza Hoda
Dr. Karin Schelch
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomolecules is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- growth factor
- signal transduction
- biomarker
- therapy target
- lung cancer
- esophageal cancer
- malignant pleural mesothelioma
- thymic malignancy
